Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2017 (2017), Article ID 9343896, 4 pages
https://doi.org/10.1155/2017/9343896
Case Report

A Rare Case of Esophageal Adenocarcinoma with Urinary Bladder Metastasis

1Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, Huntington, WV 25701, USA
2Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, Huntington, WV 25701, USA
3Department of Pathology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, Huntington, WV 25701, USA

Correspondence should be addressed to Heather Katz; ude.llahsram@hztak

Received 17 March 2017; Accepted 14 May 2017; Published 31 May 2017

Academic Editor: Daniel C. Damin

Copyright © 2017 Heather Katz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Napier, M. Scheerer, and S. Misra, “Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities,” World Journal of Gastrointestinal Oncology, vol. 6, no. 5, pp. 112–120, 2014. View at Publisher · View at Google Scholar
  2. H. Pohl, B. Sirovich, and H. G. Welch, “Esophageal adenocarcinoma incidence: are we reaching the peak?” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 6, pp. 1468–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. F. Buas and T. L. Vaughan, “Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease,” Seminars in Radiation Oncology, vol. 23, no. 1, pp. 3–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. L. S. Engel, W. Chow, T. L. Vaughan et al., “Population attributable risks of esophageal and gastric cancers,” JNCI Journal of the National Cancer Institute, vol. 95, no. 18, pp. 1404–1413, 2003. View at Publisher · View at Google Scholar
  5. A. Dubecz, I. Gall, N. Solymosi et al., “Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis,” Journal of Thoracic Oncology, vol. 7, no. 2, pp. 443–447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Makker, N. Karki, B. Sapkota, M. Niazi, and P. Remy, “Rare presentation of gastroesophageal carcinoma with rectal metastasis: a case report,” American Journal of Case Reports, vol. 17, pp. 611–615, 2016. View at Publisher · View at Google Scholar
  7. V. Velcheti and R. Govindan, “Metastatic cancer involving bladder: a review,” The Canadian Journal of Urology, vol. 14, no. 1, pp. 3443–3448, 2007. View at Google Scholar · View at Scopus
  8. J. P. Schuurman, T. S. De Vries Reilingh, S. M. Roothaan, R. T. Bijleveld, and M. J. Wiezer, “Urinary bladder metastasis from an esophageal adenocarcinoma: a case report,” American Journal of Gastroenterology, vol. 104, no. 6, pp. 1603-1604, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Matsumoto, H. Mibu, Y. Kagebayashi, and Y. Miyasaka, “Metastatic intrapelvic tumor from esophageal cancer: a case report,” Hinyokika Kiyo, vol. 50, no. 10, pp. 725–727, 2004. View at Google Scholar
  10. E. Suh, L. Chen, J. Taylor, and P. G. Traber, “A homeodomain protein related to caudal regulates intestine-specific gene transcription,” Molecular and Cellular Biology, vol. 14, no. 11, pp. 7340–7351, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. R. W. Phillips, H. F. Frierson Jr., and C. A. Moskaluk, “Cdx2 as a marker of epithelial intestinal differentiation in the esophagus,” American Journal of Surgical Pathology, vol. 27, no. 11, pp. 1442–1447, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. B. Amin, K. Trpkov, A. Lopez-Beltran, D. Grignon, and Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group, “Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference,” The American Journal of Surgical Pathology, vol. 38, no. 8, pp. e20–e34, 2014. View at Publisher · View at Google Scholar
  13. O. Kaufmann, J. Volmerig, and M. Dietel, “Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas,” American Journal of Clinical Pathology, vol. 113, no. 5, pp. 683–687, 2000. View at Publisher · View at Google Scholar · View at Scopus